← Leaderboards
Martin Clynes
State University Of New York At Buffalo
$211,468
Attributed
$845,871
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $429.4K · FY2018–19$500K$375K$250K$125K$0
'18
'19
Funding mix
By agency
NIH$845,871 · 1
By mechanism
R01$845,871 · 1
Top collaborators
- Wen Wee Ma2 shared
- Chris Scott2 shared
- Robert M Straubinger2 shared
Most similar at State University Of New York At Buffalo
Same institution · by research overlap
- Robert M Straubinger$4,875,752
- Wen Wee Ma$737,204
- Jessica L Reynolds$3,618,581
- Paras N. Prasad$3,868,715
- Chris Scott$539,205
Others in their field
Other Emerging Leaders on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Chanza Baytop · Westat, Inc.$271,217,917
- Valerie Koch · University Corporation For Atmospheric Res$247,762,266
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$211,662,224
Research focus
BaseBloodBlood FlowBlood PerfusionBlood VesselsCancer BiologyCancer CellCancer PatientCancer TherapyCetuximabCharacteristicsChemotherapyClinical DataClinically RelevantClinical TrialsCombined Modality TherapyComplexCytotoxicityDeath Receptor 5DensityDepositionDesignDiagnosisAffinity
Grant awards (2)
Tumor priming sequences combined with novel nanoparticle drug carriers for enhanced therapeutic efficacy in pancreatic cancer: a tripartite USA/Northern Ireland/Republic of Ireland consortium$416,494
R01 · FY2019 · CA
Tumor priming sequences combined with novel nanoparticle drug carriers for enhanced therapeutic efficacy in pancreatic cancer: a tripartite USA/Northern Ireland/Republic of Ireland consortium$429,377
R01 · FY2018 · CA